1. Home
  2. NNNN

as of 05-26-2026 3:53pm EST

$31.82
$2.60
-7.55%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Founded: 2021 Country:
Germany
Germany
Employees: 27 City: N/A
Market Cap: 1.2B IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 14.1K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $7.58 - $55.65 Next Earning Date: 04-07-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: 446.57 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: